StockData

ImmuCell vs Jaguar Health

ICCC and JAGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ICCC and JAGX compare

ImmuCell is the larger company, worth 51 times as much as Jaguar Health ($103M against $2.0M).

Jaguar Health grew revenue faster over the last twelve months (136% versus 8.5% for ImmuCell).

ImmuCell scores higher on the StockData Score (13 against 3 for Jaguar Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricICCCJAGX
Size and price
Market cap$103M$2.0M
Share price$11.33$0.390
Change, 1 year110%−100.0%
Change, 5 years23.2%−100%
Beta (5Y)0.745.30
Employees7347
StockData Score
Total score13 (better)3
Valuation score11
Growth score3 (better)2
Performance score4 (better)0
Health score5 (better)0
Dividend score00
Valuation
P/E142×–
P/S3.4×0.1× (better)
P/B3.3×–
EV/EBITDA16.3×–
P/FCF24.4×–
FCF yield4.1%–
Fair value$11.01–
Margin of safety−2.9%–
Growth
Revenue growth (TTM)8.5%136% (better)
Revenue growth, 5Y average12.5% (better)4.2%
Net income growth (TTM)−55.3%–
EPS growth (TTM)−57.9%–
Profitability
Gross margin40.3%82.3% (better)
Operating margin12.6% (better)−93.1%
Net margin2.6%–
FCF margin13.7%–
Return on equity2.6%–
Return on invested capital11.1%–
Financial health
Debt / equity0.26–
Net debt / EBITDA−0.09–
Interest coverage8.9× (better)−25.9×
Current ratio4.75 (better)0.69
Altman Z-score5.06 (better)−18.45
Piotroski F-score7 (better)2
Dividends and buybacks
Buyback yield0.00%–
Shareholder yield0.00%0.00%
Ownership
Held by institutions14.7%–
Held by insiders13.7%17.1%
Insider net buying, 12 months$156K–
Short interest, % of float0.19%4.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.